Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States
Aim To compare real-world dose escalation of risankizumab with other US Food and Drug Administration (FDA)-approved biologic treatments for management of moderate-to-severe psoriasis (PsO) in the United States. Methods The Merative® MarketScan® Research Database was used to identify adults with ≥2 m...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/09546634.2023.2200869 |
| _version_ | 1827816497364336640 |
|---|---|
| author | Jashin J. Wu Manish Patel Feng Zeng Ahong Huang Xing Pan Yiwen Cao Naijun Chen Huzefa Photowala Vishvas Garg Jeff Crowley |
| author_facet | Jashin J. Wu Manish Patel Feng Zeng Ahong Huang Xing Pan Yiwen Cao Naijun Chen Huzefa Photowala Vishvas Garg Jeff Crowley |
| author_sort | Jashin J. Wu |
| collection | DOAJ |
| description | Aim To compare real-world dose escalation of risankizumab with other US Food and Drug Administration (FDA)-approved biologic treatments for management of moderate-to-severe psoriasis (PsO) in the United States. Methods The Merative® MarketScan® Research Database was used to identify adults with ≥2 medical claims for PsO, ≥3 claims of the index biologic medication in the maintenance period, and ≥6 months continuous enrollment pre-induction and ≥6 months after initiation of the maintenance period. Dose escalation was defined as ≥2 dosing intervals where the average daily dose was ≥30% higher than the expected daily dose (per FDA-approved dosing). Comparisons between risankizumab and other cohorts were made using chi-square tests and logistic regression models. Results At the 30% threshold, the percentage of patients with dose escalation in the full maintenance period was significantly lower with risankizumab (2.0%) compared with other drug classes (tumor necrosis factor, interleukin (IL)-12/23, IL-17, or other IL-23 inhibitors: 17.6%, 10.0%, 18.3%, or 7.1%, respectively; p < 0.0001 for each) and individual biologics (adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab; 17.9%, 10.0%, 15.7%, 18.0%, and 7.2%, respectively; p < 0.0001). Conclusion A significantly lower proportion of risankizumab-treated patients with PsO had dose escalations compared with patients treated with other biologics. |
| first_indexed | 2024-03-12T00:15:11Z |
| format | Article |
| id | doaj.art-a9d47e3c0a2d49c78d55c475b09339ae |
| institution | Directory Open Access Journal |
| issn | 0954-6634 1471-1753 |
| language | English |
| last_indexed | 2024-03-12T00:15:11Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj.art-a9d47e3c0a2d49c78d55c475b09339ae2023-09-15T14:28:53ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532023-12-0134110.1080/09546634.2023.22008692200869Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United StatesJashin J. Wu0Manish Patel1Feng Zeng2Ahong Huang3Xing Pan4Yiwen Cao5Naijun Chen6Huzefa Photowala7Vishvas Garg8Jeff Crowley9Department of Dermatology, University of Miami Miller School of MedicineAbbVie IncTigermed-BDM IncTigermed-BDM IncTigermed-BDM IncTigermed-BDM IncAbbVie IncAbbVie IncAbbVie IncBakersfield Dermatology and Skin Cancer Medical GroupAim To compare real-world dose escalation of risankizumab with other US Food and Drug Administration (FDA)-approved biologic treatments for management of moderate-to-severe psoriasis (PsO) in the United States. Methods The Merative® MarketScan® Research Database was used to identify adults with ≥2 medical claims for PsO, ≥3 claims of the index biologic medication in the maintenance period, and ≥6 months continuous enrollment pre-induction and ≥6 months after initiation of the maintenance period. Dose escalation was defined as ≥2 dosing intervals where the average daily dose was ≥30% higher than the expected daily dose (per FDA-approved dosing). Comparisons between risankizumab and other cohorts were made using chi-square tests and logistic regression models. Results At the 30% threshold, the percentage of patients with dose escalation in the full maintenance period was significantly lower with risankizumab (2.0%) compared with other drug classes (tumor necrosis factor, interleukin (IL)-12/23, IL-17, or other IL-23 inhibitors: 17.6%, 10.0%, 18.3%, or 7.1%, respectively; p < 0.0001 for each) and individual biologics (adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab; 17.9%, 10.0%, 15.7%, 18.0%, and 7.2%, respectively; p < 0.0001). Conclusion A significantly lower proportion of risankizumab-treated patients with PsO had dose escalations compared with patients treated with other biologics.http://dx.doi.org/10.1080/09546634.2023.2200869psoriasisreal-world datadose escalation |
| spellingShingle | Jashin J. Wu Manish Patel Feng Zeng Ahong Huang Xing Pan Yiwen Cao Naijun Chen Huzefa Photowala Vishvas Garg Jeff Crowley Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States Journal of Dermatological Treatment psoriasis real-world data dose escalation |
| title | Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States |
| title_full | Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States |
| title_fullStr | Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States |
| title_full_unstemmed | Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States |
| title_short | Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States |
| title_sort | real world dose escalation of biologics for moderate to severe psoriasis in the united states |
| topic | psoriasis real-world data dose escalation |
| url | http://dx.doi.org/10.1080/09546634.2023.2200869 |
| work_keys_str_mv | AT jashinjwu realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT manishpatel realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT fengzeng realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT ahonghuang realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT xingpan realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT yiwencao realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT naijunchen realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT huzefaphotowala realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT vishvasgarg realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates AT jeffcrowley realworlddoseescalationofbiologicsformoderatetoseverepsoriasisintheunitedstates |